If You Invested in Valion Bio Inc (VBIO)
Looking for the live price? See the VBIO quote & overviewWhat $1,000 or $10,000 in VBIO Would Be Worth Today
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Apr 28, 2026 |
|---|---|---|---|---|
| $1,000 | — | — | — | $494 -51% |
| $10,000 | — | — | — | $4,940 -51% |
Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for VBIO$1,000 Investment Over Time
VBIO vs S&P 500Year-by-Year Returns
VBIO annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2026 | $1.01 | $0.50 | -50.6% | -50.6% |
About Valion Bio Inc
Electromedical & Electrotherapeutic Apparatus · NASDAQ
Valion Bio, Inc. develops immunotherapeutic biologics based on Toll-like receptor 5, or TLR5, activation for cytoprotection and immune modulation. The company, formerly known as Tivic Health Systems, Inc., trades on Nasdaq under the symbol VBIO and operates as a clinical-stage biopharmaceutical company. Its lead program is Entolimod™, a TLR5 agonist being developed for Acute Radiation Syndrome, oncology supportive care, and longevity-related indications.
Entolimod is designed to activate innate immune pathways, including cytoprotective signaling relevant to bone marrow and gastrointestinal tissue preservation after ionizing radiation exposure. The Acute Radiation Syndrome program is positioned as a medical countermeasure for radiological threats, and the company has described FDA Fast Track and Orphan Drug designations for Entolimod in ARS. Valion Bio also links Entolimod's mechanism to oncology supportive care, including potential treatment of neutropenia, a condition commonly associated with chemotherapy, and lymphocyte exhaustion, a state of T-cell dysfunction.
The company's pipeline also includes Entolasta™, a next-generation TLR5 agonist intended to broaden the therapeutic reach of the same innate-immunity platform. Entolasta provides additional pipeline depth in areas that include oncology supportive care and other applications where TLR5-mediated immune modulation may be relevant.
Pipeline and manufacturing model
Valion Bio combines drug development with internal biomanufacturing capabilities through Velocity Bioworks, its wholly owned contract development and manufacturing organization. Velocity Bioworks provides biomanufacturing services to third-party biotechnology companies and also supports Valion Bio's own biologics pipeline. This structure gives the company an operating model that includes clinical-stage therapeutic development and CDMO service activity within the same corporate group.
The company is headquartered in San Antonio, Texas. Its current corporate identity reflects a completed rebranding from Tivic Health Systems to Valion Bio, with the ticker change to VBIO effective in April 2026. The name change marks the company's stated transition from its prior health-technology identity to a biopharmaceutical platform centered on Entolimod, Entolasta, innate immunity, and biologics manufacturing.
Frequently Asked Questions
Valion Bio Inc investment returns
How much would $1,000 invested in Valion Bio Inc be worth today?
Limited historical data is available for VBIO. The stock has been trading since 2026-04-28.
Has Valion Bio Inc outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare VBIO performance over available time periods.
What is Valion Bio Inc's average annual return?
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
